Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Timothy FitzgeraldMaryia ZhdanavaDominic PilonAditi ShahPatrick LefebvreSteven R FeldmanPublished in: Dermatology and therapy (2023)